NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Detecting Beta-amyloid in the Retina

TerminatedNA

Sponsor: Center for Eye Research Australia

Conditions: Dementia, Alzheimer Disease

Interventions: Hyperspectral camera

Countries: Australia

Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides detailed information about retinal structure. Previous research has demonstrated a potential role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. This study aims to further evaluate the use of hyperspectral retinal imaging in the assessment of individuals with dementia or those at risk of Alzheimer's disease.

Eligibility overview

Sex: ALL

Age: 30 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Aged 30 years and older
* Diagnosis of Alzheimer's disease or no evidence of Alzheimer's disease (including control participants or those with other neurodegenerative conditions such as Parkinson's disease, Lewy body dementia, or vascular dementia)
* Prior confirmation of Alzheimer's disease diagnosis by genetic testing or positron emission tomography (PET) scan (where applicable)
* Able to undergo cognitive assessment if required (for control participants without recent testing within the past 6 months)
* No major ocular conditions that would preclude retinal imaging
* Willing and able to attend the Royal Victorian Eye and Ear Hospital
* Able to attend with a friend or family member

Exclusion Criteria:

* Presence of significant ocular disease that prevents adequate retinal imaging
* Inability to undergo study procedures or comply with study requirements
* Any condition that, in the opinion of the investigators, would make participation unsafe or compromise data quality

Locations (1)

Melbourne, Victoria, Australia